We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

19 hedge funds and large institutions have $925K invested in Moleculin Biotech in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

5% less funds holding

Funds holding: 20 → 19 (-1)

30% less capital invested

Capital invested by funds: $1.33M → $925K (-$401K)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
19
Holders Change
-1
Holders Change %
-5%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$207
2
UBS Group
UBS Group
Switzerland
+$207
3
Wells Fargo
Wells Fargo
California
+$207

Top Sellers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
-$44.7K
2
SCM
Sio Capital Management
New York
-$17.8K
3
TSS
Two Sigma Securities
New York
-$7.59K
4
Renaissance Technologies
Renaissance Technologies
New York
-$3.93K
5
Millennium Management
Millennium Management
New York
-$1.86K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$462K – – –
SCM
2
Sio Capital Management
New York
$116K -$17.8K -86 -11%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$105K +$207 +1 +0.2%
BlackRock
4
BlackRock
New York
$83.9K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$51K -$3.93K -19 -6%
State Street
6
State Street
Massachusetts
$30.5K – – –
Northern Trust
7
Northern Trust
Illinois
$22.9K – – –
PJSIMP
8
P.J. Schmidt Investment Management (PJS)
Wisconsin
$17.8K – – –
Millennium Management
9
Millennium Management
New York
$13K -$1.86K -9 -10%
SPC
10
Sigma Planning Corp
Michigan
$7.27K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$6.12K – – –
JE
12
JMAC Enterprises
Pennsylvania
$5.61K – – –
Morgan Stanley
13
Morgan Stanley
New York
$2.71K – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$414 – – –
Wells Fargo
15
Wells Fargo
California
$307 +$207 +1 +100%
NSIM
16
North Star Investment Management
Illinois
$107 – – –
UBS Group
17
UBS Group
Switzerland
$85 +$207 +1 New
Bank of America
18
Bank of America
North Carolina
$43 – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$15 – – –
Fidelity Investments
20
Fidelity Investments
Massachusetts
$1 – – –
Squarepoint
21
Squarepoint
New York
– -$44.7K -206 Closed
TSS
22
Two Sigma Securities
New York
– -$7.59K -35 Closed
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
– -$413 -2 -67%
CFO
24
CVA Family Office
Colorado
– -$289 -1 Closed
NS
25
NBC Securities
Alabama
– +$207 +1 New

MBRX Hedge Fund Activity: Q3 2023 in Review

19 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2023, worth a combined $925K — down 30% from $1.33M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of MBRX and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $207. The largest seller was Squarepoint, exiting entirely with an estimated $44.7K sold.

  • 19 institutional investors held Moleculin Biotech (MBRX) as of Q3 2023, down from 20 in Q2 2023.
  • Funds reported $925K of Moleculin Biotech stock for Q3 2023, down 30% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q3 2023 and 3 closed out, a net change of -1 holder.
  • The largest Moleculin Biotech buyer in Q3 2023 was Geode Capital Management, an estimated $207 added.
  • The largest Moleculin Biotech seller in Q3 2023 was Squarepoint, an estimated $44.7K sold.

Based on aggregated 13F filings for Q3 2023.